JWCA
ZYNE

J.W. Cole Advisors’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

J.W. Cole Advisors’s Portfolio ZYNE Stock Details ZYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-37,064
Closed -$123K – 908
2020
Q3 		$123K Buy
+37,064
New +$136K 0.01% 719

Other funds holding ZYNE

EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

J.W. Cole Advisors's ZYNE Position: Q4 2020 in Review

J.W. Cole Advisors sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q4 2020, closing a stake of 37,064 shares — an estimated $123K sold.

J.W. Cole Advisors first reported a position in ZYNE in Q3 2020 and held it in 1 quarter. The position peaked at $123K in Q3 2020. 58 funds tracked by Wall St. Rank hold ZYNE as of Q4 2020.

  • J.W. Cole Advisors reported no remaining Zynerba Pharmaceuticals, Inc position as of Q4 2020 after selling out during the quarter.
  • J.W. Cole Advisors sold 37,064 Zynerba Pharmaceuticals, Inc shares in Q4 2020, an estimated $123K.
  • J.W. Cole Advisors first reported a position in Zynerba Pharmaceuticals, Inc in Q3 2020 and held it in 1 quarter.
  • J.W. Cole Advisors's Zynerba Pharmaceuticals, Inc position peaked at $123K in Q3 2020.
  • 58 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q4 2020.

Based on J.W. Cole Advisors's 13F filing for Q4 2020, filed 12 Feb 2021.